NeOnc to Present NEO100 Brain Cancer Study Data at Society for Neuro-Oncology Meeting
PUBT · 2d ago
Share
Listen to the news
- NeOnc Technologies will present NEO100 and NEO212 clinical data Nov. 13, 2026, at the Society for Neuro-Oncology annual meeting in Philadelphia.
- Intranasal NEO100 results describe durable tumor remission and prolonged survival in recurrent IDH1-mutant astrocytoma, drawing on Phase 1/2a and compassionate-use experience.
- Oral NEO212 Phase 1 data cover safety and early signs of activity in treatment-resistant recurrent glioblastoma and brain metastases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800PRIMZONEFULLFEED9857541) on November 02, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending